# CorMedix Inc. (CRMD) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CRMD
## Company Profile
- Ticker: CRMD
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 7.3 USD
- Market cap: 640951949.47 USD
- Last updated: 2026-08-11
## Business Overview
### Institutional Anti-Infective Company
CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care.
### DefenCath
DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters. It is the company’s largest commercial product.
### Acquired Melinta Portfolio
The Melinta acquisition added marketed anti-infectives, including REZZAYO, and expanded CorMedix’s hospital-focused commercial organization.
### Late-Stage Expansion Programs
CorMedix is developing REZZAYO for prophylaxis of invasive fungal disease after allogeneic stem-cell transplantation and DefenCath for patients receiving total parenteral nutrition.
## Why The Stock Is Moving

As of Aug 11, 2026, CRMD closed down 3.05% at $7.30. No new same-company headline was identified in the current news window.

## Future Catalysts

- An FDA supplemental NDA submission for REZZAYO prophylaxis is expected in the second half of 2026.
- A potential commercial launch of REZZAYO in the expanded prophylaxis indication is targeted for 2027.
- The Phase 3 study of taurolidine and heparin catheter-lock solution in total parenteral nutrition patients is currently trending toward completion in 2028.

## Recent News
- 2026-07-29 12:30 EST — [CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026](https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-report-second-quarter-2026-financial-results-and-provid-d049bf35) — Source: CorMedix Inc.
- 2026-06-08 12:30 EST — [U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation](https://biopharmsignal.com/news/CRMD/u-s-court-of-appeals-for-the-federal-circuit-affirms-victory-for-cormedix-therap-ae49f299) — Source: CorMedix Inc.
- 2026-05-15 12:30 EST — [Cormedix Therapeutics to Participate in two Upcoming Investor Conferences](https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-participate-in-two-upcoming-investor-conferences-ec428c77) — Source: CorMedix Inc.
- 2026-05-14 11:30 EST — [Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-reports-first-quarter-2026-financial-results-and-provides--fa8848c2) — Source: CorMedix Inc.
- 2026-05-05 12:30 EST — [CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026](https://biopharmsignal.com/news/CRMD/cormedix-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-158d8bc3) — Source: CorMedix Inc.